Liver Cancer
Conditions
Keywords
Hepatocellular carcinoma, Transarterial chemoembolization, Gemcitabine
Brief summary
To evaluate local tumor control and survival rate after repeated transarterial chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC) patients.
Interventions
PROCEDUREtransarterial chemoembolization
Sponsors
Guangdong Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with histologically confirmed HCC with unresectable disease without extrahepatic metastases; * HCC with no previous treatment; * age between 18 and 75 years; * Life expectancy of at least 8 weeks; * main tumor size greater than 5 cm; * adequate hematologic function (platelet count: \>60 × 109 platelets/L; hemoglobin: \>90g/L; and prothrombin time: \<3 seconds above control); * adequate renal function (serum creatinine: ≤1.5 × upper limit of normal); * Child-Pugh classification A or B grade; * Barcelona Clinic Liver Cancer (BCLC) stage B or C; * Eastern Co-operative Group performance status of zero or one.
Exclusion criteria
* a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced than the nontumorous liver parenchyma on arterial phase computed tomography scans); * diffuse-type HCC; * evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy; * severe underlying cardiac or renal diseases; * color Doppler ultrasonography showing portal vein tumor thrombosis with complete main portal vein obstruction without cavernous transformation; or obstructive jaundice.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | 1-2 year |
Countries
China
Outcome results
None listed